FDLI Insighter
FDLI’s Insighter is a periodic column that offers a fresh perspective on issues affecting the food and drug industry.
If you’re interested in writing an FDLI Insighter column, please contact
Michael Levin-Epstein, Editor-in-Chief, (202) 222-0897 or mdl@fdli.org.
2009
March 12
Did the Supreme Court get Wyeth Right?
•• By Thomas N. Tiedt
February 3
Nanotechnology: Reducing Liability Exposure When Risks Are Unknown
•• By Jesse Ash, Antony Klapper and James Wood
2008
August 13
The Supreme Court Should Rule for Mrs. Levine
•• By Thomas N. Tiedt
May 28
Personalized Medicine: A Challenging Revolution in Healthcare
•• By Beryl Lieff Benderly
April 10
Foods v. Drugs: Does FDAAA § 912 Redraw the Line?
•• By Diane B. McColl and Ricardo Carvajal
February 19
FDA Should Systematically Gather Basic Nanomaterial Information
•• By John C. Monica, Jr.
January 23
FDA Begins to Tackle Nanotech Challenge
•• By Beryl Lieff Benderly
2007
November 6
FDA Appoints Risk Communication Advisory Committee
•• By Beryl Lieff BenderlySeptember 25
Fixing FDA Imports: It’s Not Rocket Science
•• By Benjamin L. EnglandJuly 20
Final Dietary Supplement cGMP Rules Stretch FDA’s Records
Inspection Authority Beyond its Limits
•• By John G. Moore, J.D., Ph.D.June 13
Rights and Responsibilities in Providing Unapproved Drug
to Dying Patients
•• By James J. Kelly, President and CEO, FDLIMarch 24
New Laws Will Mean Fewer Drugs
•• By Henry I. MillerJan 22
FDA Primed to Help Dying Patients Gain Easier Access to
Unapproved Drugs
•• By Beryl Lieff Benderly